Hyperbilirubinemia's protective effect against cisplatin nephrotoxicity in the Gunn rat

Anti-Cancer Drugs

Volumn 19, Issue 5, 2008, Pages 495-502

  Barabas, Karri ^a   Milner, Rowan ^a   Farese, James ^a   Baylis, Chris ^b   Croker, Byron ^c   Archer, Linda ^a   Adin, Christopher ^a  

^a University of Florida   (United States)

^b UNIVERSITY OF FLORIDA   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Acute; Heme oxygenase; Kidney failure; Kidney toxins

Indexed keywords

BILIRUBIN; CISPLATIN; CREATININE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BILIRUBIN BLOOD LEVEL; BLOOD SAMPLING; BODY WEIGHT; CANCER CELL CULTURE; CANCER GRADING; CELL VIABILITY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DOG; GUNN RAT; HISTOPATHOLOGY; HYPERBILIRUBINEMIA; KIDNEY FAILURE; KIDNEY FUNCTION; MALE; MICROSCOPY; NEPHROTOXICITY; NONHUMAN; OSTEOSARCOMA CELL; PRIORITY JOURNAL; RAT; RENAL PROTECTION; UREA NITROGEN BLOOD LEVEL; WISTAR RAT;

ANIMALS; ANTINEOPLASTIC AGENTS; BILIRUBIN; CELL LINE, TUMOR; CELL SURVIVAL; CISPLATIN; CREATININE; DOGS; HYPERBILIRUBINEMIA; INJECTIONS, INTRAPERITONEAL; KIDNEY; KIDNEY FAILURE, ACUTE; MALE; RATS; RATS, GUNN; RATS, WISTAR;

EID: 42349117496     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/CAD.0b013e3282fdc391     Document Type: Article

References (49)

1. Baum ES, Gaynon P, Greenberg L, Krivit W, Hammond D. Phase II trial cisplatin in refractory childhood cancer: Children's Cancer Study Group Report. Cancer Treat Rep 1981; 65:815-822.
2. Clark JR, Dreyfuss AI. The role of cisplatin in treatment regimens for squamous cell carcinoma of the head and neck. Semin Oncol 1991; 18:34-48.
3. Gasparini M, Rouesse J, van OA, Wagener T, Somers R, Russel JA, et al. Phase II study of cisplatin in advanced osteogenic sarcoma. European Organization for Research on Treatment of Cancer Soft Tissue and Bone Sarcoma Group. Cancer Treat Rep 1985; 69:211-213.
4. Giaccone G. Clinical perspectives on platinum resistance. Drugs 2000; 59 (Suppl 4):9-17.
5. Loeher PJ, Einhorn LH. Cisplatin. Ann Intern Med 1984; 100:704-713.
6. Ochs JJ, Freeman AI, Douglass HO Jr, Higby DS, Mindell ER, Sinks LF. cis-Dichlorodiammineplatinum (II) in advanced osteogenic sarcoma. Cancer Treat Rep 1978; 62:239-245.
7. Reed E. Cisplatin, carboplatin, and oxaliplatin. In: Chabner BA, Longo DL, editors. Cancer chemotherapy and biotherapy principles and practice. 4th ed. Philadelphia: Lippincott Williams and Wilkins; 2006. pp. 332-343.
8. Safirstein R, Winston J, Moel D, Dikman S, Guttenplan J. Cisplatin nephrotoxicity: insights into mechanism. Int J Androl 1987; 10:325-346.
9. Fraval HN, Rawlings CJ, Roberts JJ. Increased sensitivity of UV-repair-deficient human cells to DNA bound platinum products which unlike thymine dimers are not recognized by an endonuclease extracted from Micrococcus luteus. Mutat Res 1978; 51:121-132.
10. Clarkson TW. The pharmacology of mercury compounds. Annu Rev Pharmacol 1972; 12:375-406.
11. Levi J, Jacobs C, Kalman SM, McTigue M, Weiner MW. Mechanism of cis-platinum nephrotoxicity: I. Effects of sulfhydryl groups in rat kidneys. J Pharmacol Exp Ther 1980; 213:545-550.
12. Lieberthal W, Triaca V, Levine J. Mechanisms of death induced by cisplatin in proximal tubular epithelial cells: apoptosis vs. necrosis. Am J Physiol 1996; 270:F700-F708.
13. Kroemer G, Reed JC. Mitochondrial control of cell death. Nat Med 2000; 6:513-519.
14. Dobyan DC, Levi J, Jacobs C, Kosek J, Weiner MW. Mechanism of cis-platinum nephrotoxicity: II. Morphologic observations. J Pharmacol Exp Ther 1980; 213:551-556.
15. Tenhunen R, Marver HS, Schmid R. Microsomal heme oxygenase. Characterization of the enzyme. J Biol Chem 1969; 244:6388-6394.
16. Tenhunen R, Marver HS, Schmid R. The enzymatic conversion of heme to bilirubin by microsomal heme oxygenase. Proc Natl Acad Sci U S A 1968; 61:748-755.
17. Odell GB, Cukier JO, Gourley GR. The presence of a microsomal UDP-glucuronyl transferase for bilirubin in homozygous jaundiced Gunn rats and in the Crigler-Najjar syndrome. Hepatology 1981; 1:307-315.
18. Kirkby KA, Baylis C, Agarwal A, Croker BP, Archer L, Adin CA. Intravenous bilirubin provides incomplete protection against renal ischemia-reperfusion injury in vivo. Am J Physiol Renal Physiol 2007; 292:F888-F894.
19. Leung N, Croatt AJ, Haggard JJ, Grande JP, Nath KA. Acute cholestatic liver disease protects against glycerol-induced acute renal failure in the rat. Kidney Int 2001; 60:1047-1057.
20. Shiraishi F, Curtis LM, Truong L, Poss K, Visner GA, Madsen K, et al. Heme oxygenase-1 gene ablation or expression modulates cisplatin-induced renal tubular apoptosis. Am J Physiol Renal Physiol 2000; 278:F726-F736.
21. Tayem Y, Johnson TR, Mann BE, Green CJ, Motterlini R. Protection against cisplatin-induced nephrotoxicity by a carbon monoxide-releasing molecule. Am J Physiol Renal Physiol 2006; 290:F789-F794.
22. Dennery PA, McDonagh AF, Spitz DR, Rodgers PA, Stevenson DK. Hyperbilirubinemia results in reduced oxidative injury in neonatal Gunn rats exposed to hyperoxia. Free Radic Biol Med 1995; 19:395-404.
23. El Awady M, Chowdhury JR, Kesari K, van EH, Jansen PL, Lederstein M, et al. Mechanism of the lack of induction of UDP-glucuronosyltransferase activity in Gunn rats by 3-methylcholanthrene. Identification of a truncated enzyme. J Biol Chem 1990; 265:10752-10758.
24. Beckman Creatinine Analyzer 2 Operating Manual. Section 11: Specific Performance Characteristics, Subsection 11.4: Interferences. 1987.
25. Adin CA, Croker BP, Agarwal A. Protective effects of exogenous bilirubin on ischemia-reperfusion injury in the isolated, perfused rat kidney. Am J Physiol Renal Physiol 2005; 288:F778-F784.
26. Roncal CA, Mu W, Croker B, Reungjui S, Ouyang X, Tabah-Fisch I, et al. Effect of elevated serum uric acid on cisplatin-induced acute renal failure. Am J Physiol Renal Physiol 2007; 292:F116-F122.
27. Kadosawa T, Nozaki K, Sasaki N, Takeuchi A. Establishment and characterization of a new cell line from a canine osteosarcoma. J Vet Med Sci 1994; 56:1167-1169.
28. Barroga EF, Kadosawa T, Okumura M, Fujinaga T. Establishment and characterization of the growth and pulmonary metastasis of a highly lung metastasizing cell line from canine osteosarcoma in nude mice. J Vet Med Sci 1999; 61:361-367.
29. Bratlid D. The effect of pH on bilirubin binding by human erythrocytes. Scand J Clin Invest 1972; 29:453-459.
30. Hahm JS, Ostrow JD, Mukerjee P, Celic L. Ionization and self-association of unconjugated bilirubin, determined by rapid solvent partition from chloroform, with further studies of bilirubin solubility. J Lipid Res 1992; 33:1123-1137.
31. Mustafa MG, Cowger ML, King TE. Effects of bilirubin on mitochondrial reactions. J Biol Chem 1969; 244:6403-6414.
32. Ostrow JD, Pascolo L, Shapiro SM, Tiribelli C. New concepts in bilirubin encephalopathy. Eur J Clin Invest 2003; 33:988-997.
33. Kato Y, Shimazu M, Kondo M, Uchida K, Kumamoto Y, Wakabayashi G, et al. Bilirubin rinse: a simple protectant against the rat liver graft injury mimicking heme oxygenase-1 preconditioning. Hepatology 2003; 38:364-373.
34. Fondevila C, Shen XD, Tsuchiyashi S, Yamashita K, Csizmadia E, Lassman C, et al. Biliverdin therapy protects rat livers from ischemia and reperfusion injury. Hepatology 2004; 40:1333-1341.
35. Nakao A, Otterbein LE, Overhaus M, Sarady JK, Tsung A, Kimizuka K, et al. Biliverdin protects the functional integrity of a transplanted syngeneic small bowel. Gastroenterology 2004; 127:595-606.
36. Dore S, Takahashi M, Ferris CD, Zakhary R, Hester LD, Guastella D, et al. Bilirubin, formed by activation of heme oxygenase-2, protects neurons against oxidative stress injury. Proc Natl Acad Sci U S A 1999; 96:2445-2450.
37. Vitek L, Jirsa M, Brodanova M, Kalab M, Marecek Z, Danzig V, et al. Gilbert syndrome and ischemic heart disease: a protective effect of elevated bilirubin levels. Atherosclerosis 2002; 160:449-456.
38. Mayer M. Association of serum bilirubin concentration with risk of coronary artery disease. Clin Chem 2000; 46:1723-1727.
39. Clark JE, Foresti R, Sarathchandra P, Kaur H, Green CJ, Motterlini R. Heme oxygenase-1-derived bilirubin ameliorates postischemic myocardial dysfunction. Am J Physiol Heart Circ Physiol 2000; 278:H643-H651.
40. Foresti R, Goatly H, Green CJ, Motterlini R. Role of heme oxygenase-1 in hypoxia-reoxygenation: requirement of substrate heme to promote cardioprotection. Am J Physiol Heart Circ Physiol 2001; 281:H1976-H1984.
41. Nath KA, Haggard JJ, Croatt AJ, Grande JP, Poss KD, Alam J. The indispensability of heme oxygenase-1 in protecting against acute heme protein-induced toxicity in vivo. Am J Pathol 2000; 156:1527-1535.
42. Nomura M, Matsunami T, Kobayashi K, Uchibayashi T, Koshida K, Tanaka M, et al. Involvement of ABC transporters in chemosensitivity of human renal cell carcinoma, and regulation of MRP2 expression by conjugated bilirubin. Anticancer Res 2005; 25:2729-2735.
43. Pflueger A, Croatt AJ, Peterson TE, Smith LA, d'Uscio LV, Katusic ZS, et al. The hyperbilirubinemic Gunn rat is resistant to the pressor effects of angiotensin II. Am J Physiol Renal Physiol 2005; 288:F552-F558.
44. Hong SK, Anestis DK, Skaggs C, Brown PI, Rankin GO. The role of glucuronidation in N-(3,5-dichlorophenyl) succinimide (NDPS) nephrotoxicity: nephrotoxic potential of NDPS and NDPS metabolites in Gunn, Wistar, and Fischer 344 rats. Toxicol Appl Pharmacol 1999; 154:170-180.
45. Call NB, Tisher CC. The urinary concentrating defect in the Gunn strain of rat. Role of bilirubin. J Clin Invest 1975; 55:319-329.
46. Axelsen RA, Burry AF. Bilirubin-associated renal papillary necrosis in the homozygous Gunn rat: light-and electron-microscopic observations. J Pathol 1976; 120:165-175.
47. Mittman N, Janis R, Schlondorff D. Salicylate nephropathy in the Gunn rat: potential role of prostaglandins. Prostaglandins 1985; 30:511-525.
48. Keshavan P, Schwemberger SJ, Smith DL, Babcock GF, Zucker SD. Unconjugated bilirubin induces apoptosis in colon cancer cells by triggering mitochondrial depolarization. Int J Cancer 2004; 112:433-445.
49. Rao P, Suzuki R, Mizobuchi S, Yamaguchi T, Sasaguri S. Bilirubin exhibits a novel anti-cancer effect on human adenocarcinoma. Biochem Biophys Res Commun 2006; 342:1279-1283.